SEARCH

SEARCH BY CITATION

References

  • 1
    O'Grady J, Burroughs AK, Hardy P, Elbourne D, Truesdale A for the The UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified cyclosporin in liver transplantation: The TMC randomised controlled trial. Lancet 2002; 360: 11191125.
  • 2
    Wiesner RH. A long term comparison of tacrolimus (FK506) versus ciclosporin in liver transplantation: A report of the United States FK506 study group. Transplantation 1998; 66: 493496.
  • 3
    Pichlmayr R, Winkler P, Neuhaus P et al. Three year follow up of the European multicentre tacrolimus (FK506) liver study. Transplant Proc 1997; 29: 24992502.
  • 4
    Schafer DF, Sorrell MF. Optimising immunosuppression. Lancet 2002; 360: 11141115.
  • 5
    Levy G, Villamil F, Samuel D et al. Results of lis2t, a multicenter, randomised study comparing cyclosporin microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 6
    Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation. J Hepatol 2005; 42: 448456.
  • 7
    Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8: 1927.
  • 8
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 12811288.